Literature DB >> 19226604

Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Rosalinda C Roberts1, Joy K Roche, Robert R Conley, Adrienne C Lahti.   

Abstract

The typical symptoms of schizophrenia (SZ) are psychotic symptoms (hallucinations, delusions, disorders of thought or speech, grossly disorganized behavior) as well as cognitive impairments and negative symptoms. Not all patients respond to treatment and in those who do, only psychotic symptoms are usually improved. Imaging studies have shown that SZ subjects with high striatal dopamine release are far more responsive to antipsychotic drugs than those patients who have dopamine levels lower than or comparable to that of normal controls. In the present study we hypothesized that there was a link between psychosis and the number of dopaminergic synapses in the caudate nucleus in SZ. We examined dopaminergic synapses at the electron microscopic level in postmortem caudate from cases obtained from the Maryland Brain Collection. SZs were subdivided based on treatment response or resistance. The tissue was processed for the immunocytochemical localization of tyrosine hydroxylase (TH), the synthesizing enzyme for dopamine, and prepared for electron microscopy. The density of all TH labeled synapses was 43% greater in treatment responders than in controls and 62% greater in than in treatment resistant SZ. Axodendritic, but not axospinous, TH-labeled synapses showed this increase. TH-labeled axodendritic synapses in treatment responders were elevated in density (1.95 +/- 0.093/10 microm(3)) compared to treatment resistant SZ (0.04 +/- 0.017/10 microm(3)) and controls (0.11 +/- 0.044/10 microm(3)). The results of the present study suggest that one anatomical underpinning of good treatment response may be a higher density of dopaminergic synapses and support a biological basis to treatment response and resistance. Moreover, these data have important implications for linking specific neuropathology with particular symptoms. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226604      PMCID: PMC2770250          DOI: 10.1002/syn.20623

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  89 in total

1.  Single dopaminergic nigrostriatal neurons form two chemically distinct synaptic types: possible transmitter segregation within neurons.

Authors:  T Hattori; M Takada; T Moriizumi; D Van der Kooy
Journal:  J Comp Neurol       Date:  1991-07-15       Impact factor: 3.215

2.  Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley
Journal:  Synapse       Date:  2008-08       Impact factor: 2.562

3.  Unbiased stereological estimation of the total number of synapses in a brain region.

Authors:  Y Geinisman; H J Gundersen; E van der Zee; M J West
Journal:  J Neurocytol       Date:  1996-12

4.  High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.

Authors:  H J Coppens; C J Slooff; A M Paans; T Wiegman; W Vaalburg; J Korf
Journal:  Biol Psychiatry       Date:  1991-04-01       Impact factor: 13.382

5.  Presynaptic dopaminergic function in the striatum of schizophrenic patients.

Authors:  M H Dao-Castellana; M L Paillère-Martinot; P Hantraye; D Attar-Lévy; P Rémy; C Crouzel; E Artiges; A Féline; A Syrota; J L Martinot
Journal:  Schizophr Res       Date:  1997-02-07       Impact factor: 4.939

6.  Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis.

Authors:  L Descarries; K C Watkins; S Garcia; O Bosler; G Doucet
Journal:  J Comp Neurol       Date:  1996-11-11       Impact factor: 3.215

7.  Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis.

Authors:  C R Gerfen; J F McGinty; W S Young
Journal:  J Neurosci       Date:  1991-04       Impact factor: 6.167

8.  Cellular basis for interactions between catecholaminergic afferents and neurons containing Leu-enkephalin-like immunoreactivity in rat caudate-putamen nuclei.

Authors:  V M Pickel; J Chan; S R Sesack
Journal:  J Neurosci Res       Date:  1992-02       Impact factor: 4.164

9.  Defining treatment refractoriness in schizophrenia.

Authors:  H D Brenner; S J Dencker; M J Goldstein; J W Hubbard; D L Keegan; G Kruger; F Kulhanek; R P Liberman; U Malm; K K Midha
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

10.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  22 in total

Review 1.  Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia.

Authors:  Sabina Berretta; Stephan Heckers; Francine M Benes
Journal:  Schizophr Res       Date:  2014-11-11       Impact factor: 4.939

2.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

Review 3.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

Review 4.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

5.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

Review 6.  Towards medication-enhancement of cognitive interventions in schizophrenia.

Authors:  Hsun-Hua Chou; Elizabeth Twamley; Neal R Swerdlow
Journal:  Handb Exp Pharmacol       Date:  2012

7.  Are we studying and treating schizophrenia correctly?

Authors:  Neal R Swerdlow
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

Review 8.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

9.  Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia.

Authors:  Matej Markota; Jessica Sin; Harry Pantazopoulos; Rebecca Jonilionis; Sabina Berretta
Journal:  Schizophr Bull       Date:  2014-06-16       Impact factor: 9.306

10.  Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia.

Authors:  Vilte E Barakauskas; Annie Moradian; Alasdair M Barr; Clare L Beasley; Gorazd Rosoklija; J John Mann; Boro Ilievski; Aleksandar Stankov; Andrew J Dwork; Peter Falkai; Gregg B Morin; William G Honer
Journal:  Schizophr Res       Date:  2016-03-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.